{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:50:43Z","timestamp":1790142643747,"version":"4.0.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1097\/md.0000000000011507","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T15:34:31Z","timestamp":1531323271000},"page":"e11507","source":"Crossref","is-referenced-by-count":8,"title":["Clinical adverse effects of natalizumab"],"prefix":"10.1097","volume":"97","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Guo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Fu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-68-20210309","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-68-20210309","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"R3-68-20210309","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS","volume":"52","author":"Sheremata","year":"1999","journal-title":"Neurology"},{"key":"R4-68-20210309","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1756285617716002","article-title":"The role of natalizumab in the treatment of multiple sclerosis: benefits and risks","volume":"10","author":"Singer","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"R5-68-20210309","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"R6-68-20210309","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-68-20210309","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R8-68-20210309","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R9-68-20210309","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-68-20210309","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"R12-68-20210309","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"R13-68-20210309","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"R14-68-20210309","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"R15-68-20210309","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"R16-68-20210309","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2016.1213810","article-title":"Use of natalizumab in multiple sclerosis: current perspectives","volume":"16","author":"Gandhi","year":"2016","journal-title":"Expert Opin Biol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000011507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:17:22Z","timestamp":1620962242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201807130-00068"}},"subtitle":["Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails"],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000011507","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}